Total Payments
$488,858
2024 Payments
$63,169
Companies
23
Transactions
431
Medicare Patients
210
Medicare Billing
$19,952
Payment Breakdown by Category
Consulting$224,129 (45.8%)
Other$188,763 (38.6%)
Research$34,220 (7.0%)
Travel$33,586 (6.9%)
Food & Beverage$8,061 (1.6%)
Education$99.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $224,129 | 79 | 45.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $174,395 | 89 | 35.7% |
| Unspecified | $34,220 | 30 | 7.0% |
| Travel and Lodging | $33,586 | 105 | 6.9% |
| Honoraria | $14,368 | 3 | 2.9% |
| Food and Beverage | $8,061 | 124 | 1.6% |
| Education | $99.00 | 1 | 0.0% |
Payments by Type
General
$454,638
401 transactions
Research
$34,220
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $196,823 | 178 | $0 (2024) |
| PFIZER INC. | $98,567 | 59 | $0 (2024) |
| Janssen Biotech, Inc. | $46,378 | 46 | $0 (2024) |
| UCB, Inc. | $42,839 | 53 | $0 (2018) |
| Eli Lilly and Company | $30,649 | 28 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $18,161 | 15 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $11,203 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $10,680 | 4 | $0 (2023) |
| Lilly USA, LLC | $10,525 | 5 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $5,546 | 10 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,169 | 43 | PFIZER INC. ($14,506) |
| 2023 | $67,906 | 53 | PFIZER INC. ($17,014) |
| 2022 | $23,089 | 22 | Janssen Biotech, Inc. ($8,122) |
| 2021 | $54,212 | 26 | AbbVie Inc. ($25,861) |
| 2020 | $29,923 | 17 | PFIZER INC. ($11,748) |
| 2019 | $63,154 | 62 | AbbVie, Inc. ($27,607) |
| 2018 | $74,869 | 95 | AbbVie, Inc. ($34,823) |
| 2017 | $112,537 | 113 | AbbVie, Inc. ($78,636) |
All Payment Transactions
431 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| Category: Immunology | ||||||
| 12/09/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/03/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/08/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $4,103.25 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/08/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Travel and Lodging | Cash or cash equivalent | $2,000.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $105.30 | General |
| 10/27/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,445.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/27/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $53.89 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,034.00 | General |
| 10/15/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 10/13/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 09/06/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Rare Disease | ||||||
| 09/05/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ETRASIMOD CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 08/20/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ETRASIMOD CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 08/09/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 07/19/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ETRASIMOD CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 07/11/2024 | Medtronic, Inc. | PILLCAM (Device) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Capsule Endoscopy | ||||||
| 06/28/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,626.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 06/05/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: IMMUNOLOGY | ||||||
| 06/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $4,550.00 | Research |
| Study: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. • Category: IMMUNOLOGY | ||||||
| 06/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $52.16 | Research |
| Study: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease • Category: IMMUNOLOGY | ||||||
| 05/24/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,400.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $11,570 | 9 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,390 | 5 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | ABBVIE INC. | $4,550 | 1 |
| VELSIPITY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,150 | 4 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn's Disease | ABBVIE INC. | $829.85 | 8 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 77 | 92 | $45,987 | $7,421 |
| 2022 | 2 | 52 | 72 | $33,415 | $5,291 |
| 2021 | 2 | 43 | 46 | $14,748 | $3,977 |
| 2020 | 2 | 38 | 47 | $14,633 | $3,263 |
Total Patients
210
Total Services
257
Medicare Billing
$19,952
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 62 | $17,329 | $4,109 | 23.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 15 | 15 | $21,477 | $1,930 | 9.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 15 | $7,181 | $1,383 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 41 | 61 | $17,080 | $4,158 | 24.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 11 | 11 | $16,335 | $1,133 | 6.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 21 | 22 | $8,212 | $2,182 | 26.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 22 | 24 | $6,536 | $1,795 | 27.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 18 | 25 | $8,897 | $2,028 | 22.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 22 | $5,736 | $1,235 | 21.5% |
About Dr. Millie Long, MD
Dr. Millie Long, MD is a Internal Medicine healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336101914.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Millie Long, MD has received a total of $488,858 in payments from pharmaceutical and medical device companies, with $63,169 received in 2024. These payments were reported across 431 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($224,129).
As a Medicare-enrolled provider, Long has provided services to 210 Medicare beneficiaries, totaling 257 services with total Medicare billing of $19,952. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Chapel Hill, NC
- Active Since 04/06/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1336101914
Products in Payments
- XELJANZ (Drug) $77,275
- STELARA (Biological) $43,155
- VELSIPITY (Drug) $20,848
- SKYRIZI (Biological) $12,701
- Entyvio (Biological) $12,556
- Humira (Biological) $11,440
- OCALIVA (Drug) $11,203
- RINVOQ (Biological) $11,146
- TREMFYA (Drug) $11,140
- Cimzia (Drug) $10,728
- HUMIRA (Biological) $9,426
- XIFAXAN (Drug) $5,546
- OMVOH (Drug) $4,400
- ENTYVIO (Biological) $3,547
- ZYMFENTRA (Biological) $2,499
- ZEPOSIA (Drug) $1,980
- Non-Covered Product (Drug) $1,925
- CIMZIA (Drug) $582.16
- truFreeze (Device) $101.16
- Doptelet (Drug) $84.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chapel Hill
Dr. William Pendergraft, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $210,228
Internal Medicine $210,228
Dr. David Clemmons, Md, MD
Internal Medicine — Payments: $155,297
Internal Medicine $155,297
Dr. John Vavalle, M.d, M.D
Internal Medicine — Payments: $118,342
Internal Medicine $118,342
Dr. Hubert Ford, M.d, M.D
Internal Medicine — Payments: $85,174
Internal Medicine $85,174
Dr. Alfred Barritt, Md, MD
Internal Medicine — Payments: $82,247
Internal Medicine $82,247
Dr. Saira Sheikh, M.d, M.D
Internal Medicine — Payments: $81,497
Internal Medicine $81,497